Ideenat 100mg Tablet

Ideenat 100mg Tablet

Prescription requiredRx Required

Salt Composition: Idelalisib

Expiry Date: 01/2028

Special offer

Buy at $314.12

$314.12

Inclusive of all taxes

30 tablet

About The Product

lymphoma leukemia, 

Description

Ideenat 100mg tablet is a prescription based medication used in the treatment of lymphoma and leukemia in patient with specific genetic mutation or disease sub types that make them eligible for this therapy. Its active ingredient is Idelalisib which belongs to the group of PI3K, (phosphoinositide 3-kinase) inhibitors, a class of targeted therapies that blocks specific signaling pathways involved in the growth and survival of cancer cells in the body.

The correct dosage and duration is recommended by the healthcare professional only. Always follow the prescribed dosage and instructions provided by the doctor or pharmacist.

Uses


Leukemia and lymphoma

Side Effects

Ideenat 100mg tablet causes acute and mild symptoms that are harmful to the body. Consult the healthcare professional while experiencing any of these side effects:

  • Skin-peeling Mouth ulcer
  • Ulcer in the throat, nose, genital, and eye
  • Skin rashes
  • Fever
  • DRESS syndrome (enlarged lymph nodes)
  • Infections
  • Liver damage
  • Change in the number of WBC
  • Increased liver enzymes
  • Lung inflammation
  • Reddish patch
  • Changes in the skin color

How To Use

  • Ideenat 100mg tablet should be taken twice daily.
  • Swallow the tablet with a whole glass of water; do not crush, chew, or break the tablet.
  • Never self administered on the medication to avoid complications during the treatment.
  • Consistency is, try to take it until the doctor advises you to stop or adjust the dose.
  • Always follow the recommended dosage and duration, as it depends on the patient's weight, height, and age.

How It Works

Ideenat 100mg tablet is a targeted therapy that contains a PI3K inhibitor, which blocks the phosphoinositide 3-kinase signaling pathway, preventing the cancer cells from growing, dividing, and surviving. This medication is mainly used for individuals whose cancer cells exhibit a specific genetic mutation.

Furthermore, the medicine is used as a monotherapy for treating adult patients diagnosed with follicular lymphoma.

Safety Advice

Alcohol
Taking Ideenat 100mg tablet with alcohol may be dangerous to the patient's health but consult the doctor before taking the medication.
Pregnancy
Ideenat 100mg tablet is not recommended to pregnant and breastfeeding women as it may affect the fetus or newborn. Take guidance from a healthcare expert to ensure safety and precautions.
Breast Feeding
Breastfeeding women should not take Ideenat 100mg tablet as the medicine is passed through breast that somehow affect breast milk. Discuss with the doctor for further queries.
Driving
Ideenat 100mg tablet may not cause dizziness or sleepiness but patient may still experience some side effects. It is important to monitor the response of medication and report any unusual symptoms to the doctor.
Kidney
Kidney patients should take precautions while using Ideenat 100mg tablet as dose adjustment and doctor's prescription is much needed.
Liver
Ideenat 100mg tablet is unsafe for liver patients as this may cause common as well as severe side effects. Consult the healthcare supervisor for proper medical attention.

FAQs

Ideenat 100mg tablet is taken who is the patient of ovarian and and breast cancer.

Medicine works by stopping the growth of cancer cells in the body.

References

  • Zirlik, K., & Veelken, H. (2018). Idelalisib. Small molecules in hematology, 243-264. https://pubmed.ncbi.nlm.nih.gov/30069634/
  • Cheah, C. Y., & Fowler, N. H. (2016). Idelalisib in the management of lymphoma. Blood, The Journal of the American Society of Hematology, 128(3), 331-336. https://pubmed.ncbi.nlm.nih.gov/27252232/
  • Ramanathan, S., Jin, F., Sharma, S., & Kearney, B. P. (2016). Clinical pharmacokinetic and pharmacodynamic profile of idelalisib. Clinical pharmacokinetics, 55(1), 33-45. https://pubmed.ncbi.nlm.nih.gov/26242379/
  • Markham, A. (2014). Idelalisib: first global approval. Drugs, 74(14), 1701-1707. https://pubmed.ncbi.nlm.nih.gov/25187123/
  • Coutré, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., ... & Zelenetz, A. D. (2015). Management of adverse events associated with idelalisib treatment: expert panel opinion. Leukemia & lymphoma, 56(10), 2779-2786. https://pubmed.ncbi.nlm.nih.gov/25726955/

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026